One lot of thyroid pills tested “superpotent,” and the recall is nationwide.
Story Snapshot
- Vitruvias recalled one lot of 30 mg thyroid tablets at the consumer level.
- Testing found the product could be stronger than labeled, raising risk of hyperthyroidism.
- The affected lot is 504950, NDC 69680-166-00, with expiration 9/30/2026.
- 3,655 units released, 1,955 sold, with nationwide distribution to direct accounts.
What Was Recalled And Why It Matters
Vitruvias Therapeutics is recalling one lot of its Thyroid Tablets, United States Pharmacopeia 30 milligrams, after tests showed the product could be superpotent. The recall covers lot 504950 with National Drug Code 69680-166-00 and an expiration date of September 30, 2026.
Superpotent means the drug may deliver more hormone than the label states. That can push the body into hyperthyroidism, which can trigger chest pain, high blood pressure, fast or irregular heartbeat, and muscle weakness.
The Food and Drug Administration notice states the recall is voluntary and at the consumer level, which means patients should check their bottles and stop using the affected lot. The company reported no known adverse events tied to this recall as of the notice date.
Independent reporting matched the lot and strength details and flagged the same risks for patients. The recall aims to prevent harm before it happens, which is how the drug safety system should work when tests show a problem.
How Many Pills And Where They Went
The company released 3,655 units in this lot and reported 1,955 units sold nationwide to direct accounts from January 31, 2025, through September 30, 2025. Pharmacies and wholesalers that received these tablets should isolate inventory and follow the return instructions.
Patients who find lot 504950 should contact their pharmacy, talk to their doctor about next steps, and arrange a replacement. Doctors may order thyroid function tests if symptoms suggest excess hormone.
USA Today summarized the alert and restated the exact identifiers: 30 milligrams, lot 504950, National Drug Code 69680-166-00. That level of detail helps busy patients match the bottle in their hand to the recall.
Thyroid drugs have a narrow window between a helpful dose and a harmful dose. Even modest swings can cause jittery feelings, heat intolerance, weight loss, and sleep trouble. In older patients or those with heart disease, extra hormone can be dangerous.
What To Do If You Take Thyroid Medication
Check the bottle for “Thyroid Tablets, United States Pharmacopeia 30 mg,” the National Drug Code 69680-166-00, and lot 504950. If it matches, stop using it and call your pharmacy. Do not skip medication without a plan. Ask your doctor for guidance and a safe replacement.
Watch for signs of too much thyroid hormone: chest pain, racing heart, sweating, anxiety, tremor, or sudden weight loss. Seek urgent care for severe chest pain or fainting.
Recall: Vitruvias Thyroid Tablets USP 30 mg — lot 504950, exp. 9/30/2026, NDC 69680-166-00 — for potential superpotency.
Check your bottle. If it matches, contact your pharmacy or clinician. Do not discontinue without clinician guidance.https://t.co/rRHBYf0Ump
— The Modern Bio (@themodernbio) August 26, 2026
Report symptoms and product details through the Food and Drug Administration MedWatch program if advised. Keep the bottle until the pharmacy or the company instructs you on return or disposal.
If your bottle is a different lot or strength, stay the course as directed by your doctor. The recall is limited to this single lot. The Food and Drug Administration recall page lists current status updates for this action and other drug recalls.
Why Recalls Hit Thyroid Drugs So Often
Thyroid hormone drugs are sensitive to small potency shifts. This category shows up in recall data because both low potency and high potency can harm patients, and tests can spot drift early.
A past recall by another company cited superpotency up to 115 percent of label claim, showing how even routine checks can catch a problem before injuries mount. Broader analyses of Food and Drug Administration recalls show wrong dose or potency is a steady share of actions each year.
The Bottom Line For Patients And Clinicians
This recall is precise and preventive. The affected lot is known. The reason is clear. The risks are real but manageable when caught fast. American common sense says act now, not later: confirm the lot, replace the bottle, and protect the heart.
The Food and Drug Administration says no related adverse events have been reported so far. That is the system working before the headlines get worse. Keep care steady, verify the label, and move on with confidence.
Sources:
nypost.com, fda.gov, usatoday.com, passionhealthphysicians.com, thehill.com
